v3.26.3
Equity and Stock-Based Compensation
9 Months Ended
Sep. 30, 2026
Share-Based Payment Arrangement [Abstract]  
Equity and Stock-Based Compensation

Note 9. Equity and Stock-Based Compensation

Stock Repurchase Activity

On May 7, 2025, the Company's Board of Directors (the "Board") authorized a stock repurchase program to acquire up to $75 million of Company common stock. The amount and timing of specific repurchases are subject to market conditions, applicable legal requirements, restrictions in the Company’s debt agreements and other factors. The Company intends to fund the share repurchases using cash from operations or borrowings and may suspend or discontinue repurchases at any time. The share repurchase program expires on May 6, 2027.

The Company did not repurchase any shares of its common stock during the three months ended September 30, 2026 and incurred no associated costs. During the three months ended September 30, 2025, the Company repurchased 712,205 shares of its common stock for a total cost of $10.3 million. The Company repurchased 2,156,341 and 1,205,724 shares of its common stock in the nine months ended September 30, 2026 and 2025, respectively, for a total cost of $27.2 million and $17.0 million, respectively.

 

Stock-Based Compensation

Total stock-based compensation expense for employees and non-employees, related to all of the Company’s stock-based awards, was as follows (in thousands):

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

 

 

 

 

Cost of revenue

 

$

101

 

 

$

110

 

 

$

328

 

 

$

416

 

Selling and marketing

 

 

231

 

 

 

253

 

 

 

686

 

 

 

1,377

 

Research and development

 

 

159

 

 

 

196

 

 

 

590

 

 

 

987

 

General and administrative

 

 

555

 

 

 

827

 

 

 

2,078

 

 

 

1,526

 

Total stock-based compensation

 

$

1,046

 

 

$

1,386

 

 

$

3,682

 

 

$

4,306

 

 

The following table summarizes the total unrecognized stock-based compensation expense and remaining recognition period by Restricted Stock Units (“RSUs”) and Performance Stock Units (“PSUs”) (in thousands, except number of years):

 

 

 

September 30, 2026

 

 

 

Unrecognized Expense

 

 

Remaining weighted average period (In years)

 

 

 

 

 

 

 

 

RSUs

 

$

6,724

 

 

 

2.7

 

PSUs

 

 

2,842

 

 

 

1.4

 

Total unrecognized stock-based compensation expense

 

$

9,566

 

 

 

 

 

 

The following table presents the stock activity and the total number of shares available for grant as of September 30, 2026:

 

 

 

Number of Shares Available

 

Balance at December 31, 2025

 

 

1,849,094

 

Grants

 

 

(648,464

)

Cancelled

 

 

291,644

 

Balance as of September 30, 2026

 

 

1,492,274

 

 

Stock Option Activity

 

 

 

Options Outstanding

 

 

 

Number of
Shares
Underlying
Outstanding
Options

 

 

Weighted-
Average
Exercise
Price

 

 

Weighted-
Average
Remaining
Contractual
Term

 

 

Aggregate
Intrinsic
Value

 

 

 

 

 

 

 

 

 

(in years)

 

 

 

 

Outstanding at December 31, 2025

 

 

390,969

 

 

$

10.23

 

 

 

3.43

 

 

$

2,174,529

 

Options Granted

 

 

—

 

 

 

—

 

 

 

 

 

 

 

Options Exercised

 

 

(67,378

)

 

 

6.18

 

 

 

 

 

 

 

Options Forfeited

 

 

(8,584

)

 

 

17.54

 

 

 

 

 

 

 

Outstanding at September 30, 2026

 

 

315,007

 

 

$

10.61

 

 

 

2.57

 

 

$

1,299,090

 

Vested and expected to vest at September 30, 2026

 

 

315,007

 

 

$

10.61

 

 

 

2.57

 

 

$

1,299,090

 

Exercisable at September 30, 2026

 

 

315,007

 

 

$

10.61

 

 

 

2.57

 

 

$

1,299,090

 

 

Stock options generally vested in accordance with the terms of the applicable award agreements and are exercisable for up to ten years once vested. Vested options must be exercised within 90 days following a participant’s termination of service or they are forfeited.

There have been no options granted since the fiscal year 2021.

Restricted Stock Activity

 

 

 

Shares

 

 

Weighted
Average
Grant Date
Fair Value
Per Share

 

Nonvested restricted stock at December 31, 2025

 

 

695,367

 

 

$

14.19

 

Granted

 

 

451,184

 

 

 

10.39

 

Vested

 

 

(294,643

)

 

 

15.29

 

Forfeited

 

 

(178,174

)

 

 

14.21

 

Nonvested restricted stock at September 30, 2026

 

 

673,734

 

 

$

11.16

 

 

 

 

Performance-Based Restricted Share Activity

 

 

 

Number of
Shares
Underlying
Outstanding
Performance
Shares

 

 

Weighted
Average
Grant Date
Fair Value
Per Share

 

 

 

 

 

 

 

 

Outstanding at December 31, 2025

 

 

160,127

 

 

$

14.63

 

Granted

 

 

197,280

 

 

 

10.22

 

Released

 

 

(45,443

)

 

 

13.08

 

Forfeited

 

 

(105,667

)

 

 

11.74

 

Outstanding at September 30, 2026

 

 

206,297

 

 

$

10.89

 

 

 

The outstanding PSUs as of September 30, 2026 were comprised of 13,925, 21,999 and 170,373 performance shares that were granted on April 1, 2024, 2025 and 2026, respectively. With respect to the PSUs that were granted on April 1, 2026, the vesting is conditional based on the achievement of certain key financial and corporate strategic targets for the year ended December 31, 2026, and continued service over a three-year period. The number of units that could be earned ranged from 0% to 150% of the target shares depending on the achievement of these targets. The number of PSUs to be earned is subject to approval by the Board after the completion of the performance period based on the Company’s 2026 performance over the performance period. Approximately 17,886, 15,356, and 12,201 performance shares were released during the nine months ended September 30, 2026 relating to shares that were granted on April 1, 2023, 2024, and 2025, respectively. Earned PSUs typically vest with 33%, 33% and 34% of the earned PSU shares over the first, second and third year of the requisite vesting period, respectively.

 

Warrants

 

In January 2026, the holders exercised 550,000 wholly-funded warrants for an equal number of shares of the Company's common stock, which related to a series of transactions pursuant to the retirement of Series B preferred stock in 2018. Upon exercise, no warrants remained outstanding.